Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

BACKGROUND: Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line treatment after the failure of metformin. However, SUs are associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridderstråle, Martin, Svaerd, Robbyna, Zeller, Cordula, Kim, Gabriel, Woerle, Hans J, Broedl, Uli C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844307/
https://www.ncbi.nlm.nih.gov/pubmed/24007456
http://dx.doi.org/10.1186/1475-2840-12-129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844307/
https://www.ncbi.nlm.nih.gov/pubmed/24007456
http://dx.doi.org/10.1186/1475-2840-12-129

Ejemplares similares